Two Onc Docs ASCO Annual Meeting 2025 GU Updates
Jun 9, 2025
Explore groundbreaking advancements in genitourinary oncology presented at the 2025 ASCO Annual Meeting. Discover insights on prostate cancer, including the latest on PSA response prognostication and the Amplitude trial. Learn about innovations in treating muscle-invasive bladder cancer, especially findings from the NIAGARA trial. Key updates on renal cell carcinoma reveal adjuvant pembrolizumab's survival benefits. The discussion also highlights the role of ctDNA in personalizing treatment and improving patient outcomes across various cancers.
AI Snips
Chapters
Transcript
Episode notes
Immunotherapy Advances in Early Bladder Cancer
- Immunotherapy in non-muscle invasive bladder cancer is advancing with subcutaneous PD-1 inhibitors promising easier administration.
- Sub-Q formulations like cesanlimab and nivolumab improve patient convenience without compromising efficacy.
ctDNA Prognostic Role in Bladder Cancer
- ctDNA positivity before cystectomy predicts poor pathological response and worse event-free survival in muscle-invasive bladder cancer.
- Clearance of ctDNA is higher with immunotherapy and is a promising prognostic marker though predictive value remains unknown.
Managing Metastatic Bladder Cancer Toxicity
- Counsel patients on potential toxicities of enfortumab vedotin, including neuropathy and dermatologic effects.
- Explore personalized dosing or treatment de-escalation to balance efficacy and quality of life.